Ginkgo Bioworks Holdings, Inc. (DNA) vs Nuvectis Pharma, Inc. (NVCT)
Ginkgo Bioworks Holdings, Inc. and Nuvectis Pharma, Inc. are both Biotechnology companies. Ginkgo Bioworks Holdings, Inc. and Nuvectis Pharma, Inc. are of similar size ($706.1M and $683.6M). Nuvectis Pharma, Inc. has the higher net margin (0.00% vs −219.6%) and the higher return on invested capital (0.00% vs −161.9%). Across the 12 metrics below, Nuvectis Pharma, Inc. leads on 7 and Ginkgo Bioworks Holdings, Inc. on 5.
Valuation
Profitability
| Metric | DNA | NVCT | Biotechnology median |
|---|---|---|---|
| Gross margin | 68.04% | — | 65.16% |
| Operating margin | (231.13%) | 0.00% | 0.00% |
| Net margin | (219.60%) | 0.00% | 0.00% |
| Free cash flow margin | (131.57%) | 0.00% | 0.00% |
| Return on equity | (56.29%) | (233.30%) | (57.72%) |
| Return on assets | (26.19%) | (122.61%) | (49.22%) |
| Return on invested capital | (161.94%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack